

**NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE**

**Review Proposal Project**

**NICE Technology Appraisal Guidance Nos 103/ 134/ 146 /180; etanercept, infliximab, adalimumab and ustekinumab for the treatment of psoriasis**

**Provisional matrix of consultees and commentators**

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• Abbott Laboratories Ltd (adalimumab)</li> <li>• Janssen-Cilag (ustekinumab)</li> <li>• Pfizer (etanercept)</li> <li>• Schering-Plough Ltd (infliximab)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Afiya Trust</li> <li>• Black Health Agency</li> <li>• Changing Faces</li> <li>• Chinese National Healthy Living Centre</li> <li>• Counsel and Care</li> <li>• Equalities National Council</li> <li>• Muslim Council of Britain</li> <li>• Muslim Health Network</li> <li>• Psoriasis and Psoriatic Arthritis Alliance</li> <li>• Psoriasis Association</li> <li>• Skin Care Campaign</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• British Association for Services to the Elderly</li> <li>• British Association of Dermatologists</li> <li>• British Dermatological Nursing Group</li> <li>• British Geriatric Society</li> <li>• British Skin Foundation</li> <li>• Primary Care Dermatology Society</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Commissioning Support Appraisals Service</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• NHS Quality Improvement Scotland</li> <li>• Public Health Wales NHS Trust</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Possible comparator manufacturer(s)</u></p> <ul style="list-style-type: none"> <li>• none</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• British Epidermo-Epidemiology Society</li> <li>• Cochrane Skin Group</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> <li>• Policy Research Institute on Ageing and Ethnicity</li> <li>• Research Institute of the Care of the Elderly</li> <li>• Skin Research Centre</li> <li>• Skin Treatment and Research Trust</li> </ul>

National Institute for Health and Clinical Excellence  
 NICE Technology Appraisal Guidance Nos 103/ 134/ 146 /180; etanercept, infliximab, adalimumab and ustekinumab for the treatment of psoriasis

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• United Kingdom Clinical Pharmacy Association</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• Merthyr Tydfil LHB</li> <li>• NHS Hillingdon</li> <li>• Welsh Assembly Government</li> </ul>	<p><u>Assessment Group</u></p> <ul style="list-style-type: none"> <li>• National Institute for Health Research Health Technology Assessment Programme</li> <li>• tbc</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• National Clinical Guideline Centre</li> <li>• tbc</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• none</li> </ul>

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTees AND COMMENTATORS***

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

#### Assessment team

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).

---

<sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.